samedan logo
 
 
 
spacer
home > pmps > autumn 2020 > the future of the pharma ecosystem post-covid-19
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Future of the Pharma Ecosystem Post-COVID-19

The ongoing global pandemic has caused complete upheaval across the world for individuals and businesses alike. Within the pharmaceutical and life science industry, the need to develop a vaccine quickly is putting immense pressure on a workforce that is arguably already stretched, as skills shortages continue to have an effect on resources. However, while the pandemic has certainly presented a number of challenges, it has also created opportunities that have the potential to help alleviate many long-standing recruitment barriers.

So, what impact has COVID-19 had on talent acquisition across the life science and pharma industry?

A Changing Talent Landscape

STEM skills shortages have been widely discussed for some time now, and anyone in the pharma or life science arena will certainly be acutely aware of the talent challenges facing almost every firm in the field. The simple truth is that following a career in STEM-related professions doesn’t appeal to enough individuals in education to ensure a steady stream of newly trained recruits to meet demand on a global scale. With digital skills in limited supply, but high demand across almost every sector, attracting tech talent into pharma and the life science industry isn’t easy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jim Sykes has 20 years’ experience in talent acquisition and holds significant international experience, having supported clients and managed teams on a global basis. He is responsible for client relationships and delivery within the pharma and life science sector and the professional and business services sector at Alexander Mann Solutions.
spacer
Jim Sykes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate

The Phase 3 ENSEMBLE study (NCT04505722) of the single-dose regimen of JNJ-78436735, the investigational vaccine candidate for the prevention of COVID-19 being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, continues to enrol and vaccinate study participants. ENSEMBLE is proceeding to enrol up to 60,000 participants worldwide.1
More info >>

White Papers

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific.

Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement